Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01178411 · OUTCOME

Extent of Exposure to ARQ 197 in Participants Benefiting From Prior ARQ 197 Therapy

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols · Source last updated 2021-03-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Days
Interval / dispersion
Full Range
Time frame
Up to 3,021 days (up to 14-Jan-2019)

What was measured

The duration of ARQ 197 exposure in this study was calculated as \[(date of last dose of study drug - date of first dose of study drug) + 1\]. Results refer to duration of ARQ 197 treatment in the present study only (i.e., does not include treatment received during participation in "feeder" studies).

Analysis population: All participants who received ≥1 dose of study drug are included.

Groups in this outcome

Tivantinib (Monotherapy or Combination)

Participants received tivantinib 360 mg twice daily by mouth as monotherapy or combination therapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Tivantinib (Monotherapy or Combination)60

Reported measurements

Source class 1
Values in Days · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Tivantinib (Monotherapy or Combination)125Not reported53021Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        5
        upper Limit
        3021
        value
        125
denoms
  1. counts
    1. group Id
      OG000
      value
      60
    units
    Participants
description
The duration of ARQ 197 exposure in this study was calculated as \[(date of last dose of study drug - date of first dose of study drug) + 1\]. Results refer to duration of ARQ 197 treatment in the present study only (i.e., does not include treatment received during participation in "feeder" studies).
dispersion Type
Full Range
groups
  1. description
    Participants received tivantinib 360 mg twice daily by mouth as monotherapy or combination therapy.
    id
    OG000
    title
    Tivantinib (Monotherapy or Combination)
param Type
MEDIAN
population Description
All participants who received ≥1 dose of study drug are included.
reporting Status
POSTED
time Frame
Up to 3,021 days (up to 14-Jan-2019)
title
Extent of Exposure to ARQ 197 in Participants Benefiting From Prior ARQ 197 Therapy
type
PRIMARY
unit Of Measure
Days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice